广东新药有望定义全球癌症治疗金标准；海思科与礼来开展战略合作

21世纪经济报道06-02 08:00

政策动向　　2025年儿童用药批准量创新高连续五年稳步增长　　5月31日，国家药监局发布最新数据，2025年我国批准儿童用药138个，创历史新高。这也是我国儿童新药审批数量连续第五年实现增长。近年来，随着国家多项鼓励政策加速落地，长期以来儿童用药“品种少、规格缺、剂型不适宜”的困境正逐步破解，儿童用药“剂量靠猜、用药靠掰”的现象将加速成为历史。　　国家卫健委：儿童用药与成人用药不同不能擅自掰开成人...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2640998219?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-06-02 08:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2640998219","market":"us","top_or_hot":-1,"title":"广东新药有望定义全球癌症治疗金标准；海思科与礼来开展战略合作","media":"21世纪经济报道","content":"<div>\n<p>政策动向　　2025年儿童用药批准量创新高连续五年稳步增长　　5月31日，国家药监局发布最新数据，2025年我国批准儿童用药138个，创历史新高。这也是我国儿童新药审批数量连续第五年实现增长。近年来，随着国家多项鼓励政策加速落地，长期以来儿童用药“品种少、规格缺、剂型不适宜”的困境正逐步破解，儿童用药“剂量靠猜、用药靠掰”的现象将加速成为历史。　　国家卫健委：儿童用药与成人用药不同不能擅自掰开成人...</p>\n\n<a href=\"http://finance.eastmoney.com/a/202606023756683791.html\">网页链接</a>\n\n</div>\n","source":"stock_eastmoney","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>广东新药有望定义全球癌症治疗金标准；海思科与礼来开展战略合作</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n广东新药有望定义全球癌症治疗金标准；海思科与礼来开展战略合作\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-06-02 08:00 北京时间&nbsp;&nbsp;&nbsp;<a href=http://finance.eastmoney.com/a/202606023756683791.html><strong>21世纪经济报道</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>政策动向　　2025年儿童用药批准量创新高连续五年稳步增长　　5月31日，国家药监局发布最新数据，2025年我国批准儿童用药138个，创历史新高。这也是我国儿童新药审批数量连续第五年实现增长。近年来，随着国家多项鼓励政策加速落地，长期以来儿童用药“品种少、规格缺、剂型不适宜”的困境正逐步破解，儿童用药“剂量靠猜、用药靠掰”的现象将加速成为历史。　　国家卫健委：儿童用药与成人用药不同不能擅自掰开成人...</p>\n\n<a href=\"http://finance.eastmoney.com/a/202606023756683791.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SG9999014898.SGD","symbol_name":"United Global Quality Growth Fund Dis SGD","start_time":0,"source_url":"http://finance.eastmoney.com/a/202606023756683791.html","article_id":"2640998219","we_media_id":null,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202606023756683791.html","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2640998219","pubTimestamp":1780358400,"columns":[],"sourceInfo":{"source_id":"stock_eastmoney","name":"东方财富"},"weMediaInfo":null,"summary":"政策动向2025年儿童用药批准量创新高连续五年稳步增长5月31日，国家药监局发布最新数据，2025年我国批准儿童用药138个，创历史新高。这也是我国儿童新药审批数量连续第五年实现增长。近年来，随着国家多项鼓励政策加速落地，长期以来儿童用药“品种少、规格缺、剂型不适宜”的困境正逐步破解，儿童用药“剂量靠猜、用药靠掰”的现象将加速成为历史。","collect":0,"end_time":0,"defaultTopTitle":"eastmoney.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"SG9999014898.SGD":"United Global Quality Growth Fund Dis SGD","SG9999018865.SGD":"United Global Quality Growth Fd Cl Dist SGD-H","BK0188":"融资融券","LU1267930730.SGD":"富兰克林美国机遇基金AS Acc SGD (CPF)","SG9999015952.SGD":"LIONGLOBAL DISRUPTIVE INNOVATION \"I\" (SGD) ACC","LU2112291526.USD":"BGF WORLD HEALTHSCIENCE \"A4\" (USD) INC","LU1548497426.USD":"安联环球人工智能AT Acc","ELIL":"2倍做多LLY ETF-Direxion","LU2491050154.USD":"WELLINGTON SUSTAINABLE OUTCOMES \"A\" (USD) ACC","LU2456880835.USD":"ALLIANZ GLOBAL INCOME \"AT\" (USD) ACC","LLY":"礼来","LU0256863902.USD":"ALLIANZ US EQUITY \"AT\" (USD) ACC","LU2361044949.HKD":"WELLINGTON US QUALITY GROWTH \"A\" (HKD) ACC","BK0028":"国家队","ELIS":"1倍做空LLY ETF-Direxion","002653":"海思科","LLII":"REX LLY Growth & Income ETF","LU2552382132.HKD":"WELLINGTON US BRAND POWER \"A\" (HKD) ACC","LU2168564222.USD":"AZ ALLOCATION - TREND \"AAZ\" (USDHDG) ACC","LU2462157665.USD":"ALLIANZ GLOBAL INCOME \"A\" (USD) INC","IE00BK4W5M84.HKD":"HSBC GLOBAL FUNDS ICAV US EQUITY INDEX \"HC\" (HKD) ACC","LU2471134523.USD":"INVESCO GLOBAL EQUITY INCOME ADVANTAGE \"A\" (USD) ACC","LLYX":"2倍做多LLY ETF-Defiance","LU2265009873.SGD":"Eastspring Investments - Global Growth Equity AS SGD-H","SG9999013999.USD":"UOB UNITED GLOBAL HEALTHCARE FUND (USDHDG) INC","LLYZ":"2倍做空LLY ETF-Defiance","IE00BFSS7M15.SGD":"Janus Henderson Balanced A Acc SGD-H","LU2471134796.USD":"INVESCO GLOBAL EQUITY INCOME ADVANTAGE \"A\" (USD) INC","LU2361045086.USD":"WELLINGTON US QUALITY GROWTH \"A\" (USD) ACC","LU2417539215.USD":"ALLIANZ GLOBAL INCOME \"AMF\" (USD) INC","LU0225283273.USD":"SCHRODER ISF GLOBAL EQUITY ALPHA \"A\" (USD) ACC","LU0122379950.USD":"贝莱德世界健康科学A2","LU0133085943.USD":"T ROWE PRICE US BLUE CHIP EQUITY \"A\" ACC","SGXZ31699556.SGD":"UGDP UNITED GLOBAL QUALITY GROWTH \"C\" (SGDHDG) ACC","IE00BFSS8Q28.SGD":"Janus Henderson Balanced A Inc SGD-H","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","BK4585":"ETF&股票定投概念","BK0033":"西藏振兴","LU2063271972.USD":"富兰克林创新领域基金","LU1814569148.SGD":"WELLINGTON GLOBAL QUALITY GROWTH \"D\" (SGDHDG) ACC","IE0004445015.USD":"JANUS HENDERSON BALANCED \"A2\" (USD) ACC","LU2237443382.USD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A MIncA USD","LU1551013425.SGD":"Allianz Income and Growth Cl AMg2 DIS H2-SGD","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","LU0266013472.USD":"AXA WF - Framlington Longevity Economy A Cap USD","SG9999001176.USD":"United Global Healthcare Acc USD","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","LU1035775433.USD":"AB SICAV I - AMERICAN GROWTH PORTFOLIO \"AD\" (USD) INC","LU2236285917.USD":"ALLIANZ GLOBAL INCOME \"AMG\" (USD) INC","LU0158827948.USD":"ALLIANZ GLOBAL SUSTAINABILITY \"A\" (USD) INC"},"translate_title":"Guangdong's new drugs are expected to define the global gold standard for cancer treatment; Haisco and Eli Lilly launch strategic collaboration","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ELIS":0.6,"LLYZ":0.6,"LLII":0.6,"ELIL":0.6,"002653":1.5,"LLY":1.5,"LLYX":0.6},"content_text":"政策动向　　2025年儿童用药批准量创新高连续五年稳步增长　　5月31日，国家药监局发布最新数据，2025年我国批准儿童用药138个，创历史新高。这也是我国儿童新药审批数量连续第五年实现增长。近年来，随着国家多项鼓励政策加速落地，长期以来儿童用药“品种少、规格缺、剂型不适宜”的困境正逐步破解，儿童用药“剂量靠猜、用药靠掰”的现象将加速成为历史。　　国家卫健委：儿童用药与成人用药不同不能擅自掰开成人药片给孩子服用　　6月1日，国家卫生健康委举行新闻发布会，介绍儿童用药误区等相关情况。专家介绍，儿童不是成人的缩小版。儿童的肝脏、肾脏功能尚未发育成熟，对药物的代谢和排泄能力远低于成人。同样的药物、同样的剂量，成人可能安全，但儿童就可能蓄积中毒。　　药械审批　　新华制药：获得碳酸司维拉姆干混悬剂药品注册证书　　新华制药(000756.SZ)公告称，公司收到国家药监局核准签发的碳酸司维拉姆干混悬剂《药品注册证书》，该药品用于控制正在接受透析治疗的慢性肾脏病（CKD）成人患者的高磷血症，用于控制血清磷≥1.78mmol/L但并未进行透析的慢性肾脏病成人患者的高磷血症。本品属于医保乙类品种，2025年中国公立医疗机构司维拉姆相关制剂销售额约7.5亿元。此次获批丰富了公司制剂产品线，有利于提升综合竞争力。　　中国1类静脉麻醉创新药环泊酚获美国FDA批准上市　　海思科宣布，其自主研发的1类静脉麻醉创新药——环泊酚注射液，近日正式获得美国食品药品监督管理局（FDA）上市批准，用于成人全身麻醉诱导适应症。环泊酚因此成为中国首个走向国际的静脉麻醉原研创新药。　　长春高新：子公司注射用GenSci136获FDA批准开展临床试验　　长春高新(000661.SZ)公告称，公司子公司金赛药业收到美国FDA批准文件，同意注射用GenSci136在美国开展临床试验，适应症为重症肌无力。该药品为自主研发的BCMA三聚体融合蛋白，属治疗用生物制品1类药物，有望为患者提供更优治疗选择。　　行业大事　　万泰生物：九价HPV疫苗提交WHO PQ认证申请　　万泰生物(603392.SH)公告称，公司全资子公司万泰沧海向世界卫生组织提交了九价HPV疫苗的PQ认证申请。该疫苗为我国首款、全球第二款九价HPV疫苗，已于2025年获国家药监局注册，适用于9-45岁女性。认证结果存在不确定性，不会对近期业绩产生重大影响。　　海思科：与礼来在多个疾病领域的创新药物研发开展战略合作　　海思科（002653.SZ）公告称，公司的全资子公司海思科医药科技（拉萨）有限公司与美国礼来签署《授权与研发合作协议》，双方将在多个疾病领域的创新药物研发方面开展战略合作。根据协议，公司将依托成熟的小分子创新技术平台及高效的新药开发能力，负责礼来选定的最多五个靶点创新药项目的发现及早期研发工作。　　广东新药有望定义全球癌症治疗的金标准　　5月31日，在2026年美国临床肿瘤学会（ASCO）年会上，康方生物自主研发的全球首创PD-1/VEGF双特异性抗体依沃西新药研究（HARMONi-6研究）成果发布。该新药使得肺鳞癌患者的死亡风险降低34%，同时HARMONi-6研究也是ASCO成立61年来，首个进入全体大会的中国原创新药研究，这意味着中国创新药有能力重新定义全球癌症治疗的金标准。　　资本市场　　科源制药：股东拟询价转让占公司总股本4.90%的股份　　6月1日，科源制药(301281.SZ)公告称，公司股东济南安富创业投资合伙企业(有限合伙)拟通过询价转让方式转让531万股，占公司总股本的4.90%。转让原因为自身资金需求，受让方为具备相应定价能力和风险承受能力的机构投资者，受让后6个月内不得转让。　　舆情预警　　宏源药业：补缴2025年度企业所得税税款1856.73万元　　宏源药业(301246.SZ)公告称，经自查，公司需补缴2025年度企业所得税税款1856.73万元。截至本公告披露日，公司已按照要求将上述税款全部缴纳完毕。上述补缴的税款将计入公司2026年当期损益，对公司2026年度归属于上市公司股东的净利润的具体影响金额，最终以会计师事务所审计的财务报表为准。（文章来源：21世纪经济报道）","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2640998219","isCrawlerRequest":true}